CRD-4730 for Heart Failure With Reduced Ejection Fraction

A Trial of CRD-4730 in HFrEF

Recruiting Phase 2 Interventional Study
Heart Failure With Reduced Ejection Fraction (HFrEF)
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
525 (estimated)
Sponsor
Cardurion Pharmaceuticals, Inc. · Industry
Who this trial is looking for

This trial is looking for adults with heart failure that reduces the heart's ability to pump blood. Participants will take either a study drug or placebo twice a day for 24 weeks while receiving their usual heart failure treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old and no older than 85.
  • I have been diagnosed with chronic heart failure for at least 8 weeks.
  • My heart's pumping ability is 40% or lower.
  • My NT-proBNP level is 600 pg/mL or higher.

You may not be able to join if

  • I have been hospitalized for heart failure in the last 4 weeks.
  • I need regular IV treatments for heart failure.
  • I have had major heart or brain surgery in the last 8 weeks.
  • I have signs of specific heart muscle diseases.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult male or female patient ≥ 18 years of age and ≤ 85 years of age at the time of screening. * Has a medical history supporting a diagnosis of clinical chronic heart failure (HF) syndrome with a duration of at least 8 weeks prior to the time of screening and current NYHA fun…
Contacts

Cardurion Pharmaceuticals

617-863-8088

ClinicalTrialsGov@cardurion.com

CONTACT